J. Gutheil

发表

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2001, Oncology.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Lyndsay N Harris, L. Harris, S. Shak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antineoplastic activity of poly(L-lysine) with some ascites tumor cells.

N. Kaplan, J. Gutheil, A. Dagan, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

G. Batist, J. Gutheil, M. Nair, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.

J. Kirkwood, R. Gonzalez, S. O’Day, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Curing Cancer: The Story of the Men and Women Unlocking the Secrets of Our Deadliest Illness

J. Gutheil, J. Gutheil, 1998 .

Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

J. Thompson, A. Stopeck, R. Gonzalez, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.

S. Clarke, J. Zalcberg, J. Gutheil, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

J. Leonard, C. Redfern, J. Gutheil, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel immunologic and biologic therapies for breast cancer

J. Gutheil, 2000, Current oncology reports.

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.

L. Gordon, D. Silverman, J. Gutheil, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation.

S. Mane, J. Testa, J. Gutheil, 1990, Hematologic pathology.

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

J. Gutheil, D. Vaughn, M. Hussain, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.

S. Clarke, J. Zalcberg, J. Gutheil, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

S. Phuphanich, T. Batchelor, M. Chamberlain, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The promise of monoclonal antibodies for the therapy of cancer.

J. Gutheil, 2001, Critical reviews in oncology/hematology.

Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.

C. Serdar, J. Gutheil, L. Rosen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis

M. Gilbert, W. Mason, E. Wong, 2004, Journal of Neuro-Oncology.

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.

L. Gordon, D. Silverman, J. Gutheil, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

D. Lamm, K. Chamie, J. Gutheil, 2017, Urologic oncology.

Development of a Charter for an Endpoint Assessment and Adjudication Committee

S. Einstein, D. Kaslow, J. Gutheil, 2005 .

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

L. Recht, M. Gilbert, W. Mason, 2001, British Journal of Cancer.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

W. Denny, W. Wilson, J. Gutheil, 2010, Cancer Chemotherapy and Pharmacology.

Thalidomide therapy in refractory solid tumour patients

J. Gutheil, D. Finucane, 2000, British journal of haematology.

An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.

J. Gutheil, L. Doyle, J. Ordonez, 1995, British Journal of Cancer.

Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin.

J. Gutheil, S. Hart, C. Belani, 1994, The Journal of biological chemistry.

RAS Gene Product Expression in Blood and Marrow Smears of Patients with Acute Leukemia: Importance of Fixation

S. Mane, J. Gutheil, G. Chana, 1990, Pathology.

RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination

Edward J. Lee, S. Mane, J. Gutheil, 1990, Genes, chromosomes & cancer.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

L. Harris, D. Tripathy, S. Shak, 2001, European journal of cancer.

A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors

W. Denny, W. Wilson, J. Gutheil, 2007 .

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma

A. Stopeck, R. Gonzalez, E. Hersh, 2001 .

Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7 , an HLA-B 7 / 2-Microglobulin DNA-Liposome Complex , in Patients with Metastatic Melanoma 1

A. Stopeck, R. Gonzalez, E. Hersh, 2001 .

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

T. N. Campbell, W. Huse, J. Gutheil, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

J. Gutheil, J. Butler, A. Lobuglio, 2000, Seminars in oncology.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId® (Id/KLH) Vaccine Following Rituximab.

J. Winter, J. Hainsworth, C. Redfern, 2005 .

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum.

J. Gutheil, E. Zuhowski, M. Egorin, 1994, Journal of chromatography. B, Biomedical applications.

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

L. Harris, S. Shak, M. Cobleigh, 2001, European journal of cancer.

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.

M. Lowery, A. Varghese, P. Klein, 2017 .

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

R. Holcombe, G. Abou-Alfa, M. Mulcahy, 2011, Cancer Chemotherapy and Pharmacology.

Phase II trial of HLA-b7 plasmid dna/lipid (allovectin-7®) immunotherapy in patients with metastatic melanoma

M. Atkins, R. Gonzalez, L. Hutchins, 2001 .

Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 9~ Anti-CD20 Monoclonal Antibody 1

L. Gordon, D. Silverman, J. Gutheil, 1999 .

Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21.

S. Mane, J. Gutheil, S. Needleman, 1989, Human pathology.

MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL

D. Lamm, K. Chamie, J. Gutheil, 2019, Journal of Urology.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Lamm, K. Chamie, J. Gutheil, 2017, Urologic oncology.

A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug administered on a weekly schedule in patients with solid tumors

J. Gutheil, M. McKeage, M. Jameson, 2008 .

A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors

W. Denny, W. Wilson, J. Gutheil, 2008 .